Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Open accessAbstract
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myeloma (MM) patient samples. We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ MM cell lines in vitro (H929 cells, 50% effective concentration [EC50] = 0.15 nM; MM.1R cells, EC50 = 0.06 nM; RPMI 8226 cells, EC50 = 0.45 nM) with concomitant T-cell activation (H929 cells, EC50 = 0.21 nM; MM.1R cells, EC50 = 0.1 nM; RPMI 8226 cells, EC50 = 0.28 nM) and cytokine release. This activity was further increased in the presence of a γ-secretase inhibitor (LY-411575). Teclistamab also depleted BCMA+ cells in bone marrow samples from MM patients in an ex vivo assay with an average EC50 value of 1.7 nM. Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells. Antitumor activity of teclistamab was also observed in 2 BCMA+ MM murine xenograft models inoculated with human T cells (tumor inhibition with H929 model and tumor regression with the RPMI 8226 model) compared with vehicle and antibody controls. The specific and potent activity of teclistamab against BCMA-expressing cells from MM cell lines, patient samples, and MM xenograft models warrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy, #NCT04108195) are ongoing for patients with relapsed/refractory MM.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
This effect occurs regardless of T-cell-receptor specificity or major histocompatibility complex class I molecules on the surface of myeloma cells.
“This effect occurs regardless of T-cell–receptor specificity or major histocompatibility complex class I molecules on the surface of myeloma cells.18”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [18]
Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [18]
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1× · see citing works
“MM is characterized by overproduction of M protein, which can lead to bone lesions, increased susceptibility to infections, anemia, hypercalcemia, and renal insufficiency.(2) Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape o…”
BackgroundPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · cited 1× · see citing works
“Multiple myeloma (MM) is a malignant plasma cell disorder that leads to clonal proliferation of terminally differentiated plasma cells in the bone marrow (BM) and accounts for ;10% of all hematologic cancers.(1) MM is characterized by overproduction of M protein, which can lead to bone lesions, increased susceptibilit…”
BackgroundRaje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164 · see citing works
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · cited 1× · see citing works
“Therapeutic approaches such as chimeric antigen receptor T-cell therapies and bispecific T-cell engagers that use T cell–mediated cytotoxicity to target BCMA on plasma cells have shown deep responses in patients with relapsed or refractory disease.(21-25) Another class of T-cell redirecting therapy in development for…”
BackgroundElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · see citing works
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J. V., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J. E., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,175 · cited 2× · see citing works
“Upon binding to its ligands, a proliferation-inducing ligand (APRIL; CD256) and BAFF (CD257), BCMA activates p38/NF-kB and induces upregulation of antiapoptotic proteins to regulate B-cell maturation, proliferation, and survival.(16-20) Increased levels of a soluble form of BCMA (sBCMA), produced through cleavage at t…”
BackgroundTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundJohnson, J. I., Decker, S., Zaharevitz, D. W., Rubinstein, L., Venditti, J. M., Schepartz, S. A., Kalyandrug, S., Christian, M. C., Arbuck, S. G., Hollingshead, M. G., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856 · cited 1× · see citing works
“As defined by National Cancer Institute criteria,$60% TGI is considered biologically significant.(32) Animals were removed from the studies when a maximum tumor volume of $1500 mm(3) was reached or when adverse clinical signs of pain and distress were noted.”
BackgroundLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundBrudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 778 · cited 3× · see citing works
“Therapeutic approaches such as chimeric antigen receptor T-cell therapies and bispecific T-cell engagers that use T cell–mediated cytotoxicity to target BCMA on plasma cells have shown deep responses in patients with relapsed or refractory disease.(21-25) Another class of T-cell redirecting therapy in development for…”
BackgroundResultKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721 · see citing works
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 656 · cited 1× · see citing works
“B-cell maturation antigen (BCMA, CD269, TNFRSF17) is a 20 kDa receptor that is selectively expressed in the B-cell lineage and is also widely expressed on MM cells (in addition to smoldering MM and monoclonal gammopathy of undetermined significance).(14-16) Upon binding to its ligands, a proliferation-inducing ligand…”
BackgroundMoreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558 · cited 1× · see citing works
“4 nM, at which point a significant decrease in potency was observed (Figure 4C); these concentrations are higher than that observed in myeloma patients.(34) In contrast, exogenous BAFF had no impact.”
ResultExpression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J. A., Greipp, P. R., & Jelinek, D. F. (2003) · Blood · doi:10.1182/blood-2003-06-2043 · Cited by 556 · cited 1× · see citing works
“B-cell maturation antigen (BCMA, CD269, TNFRSF17) is a 20 kDa receptor that is selectively expressed in the B-cell lineage and is also widely expressed on MM cells (in addition to smoldering MM and monoclonal gammopathy of undetermined significance).(14-16) Upon binding to its ligands, a proliferation-inducing ligand…”
BackgroundHarousseau, J., Attal, M., Avet‐Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T. T. F., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 529 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundZhao, W., Liu, J., Wang, B., Chen, Y., Cao, X.-M., Yang, Y., Zhang, Y., Wang, F., Zhang, P., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 520 · see citing works
Thompson, J. S., Schneider, P., Kalled, S. L., Wang, L., Lefèvre, E. A., Cachero, T. G., Mackay, F., Bixler, S. A., Zafari, M. R., Liu, Z., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.129 · Cited by 393 · cited 1× · see citing works
“Upon binding to its ligands, a proliferation-inducing ligand (APRIL; CD256) and BAFF (CD257), BCMA activates p38/NF-kB and induces upregulation of antiapoptotic proteins to regulate B-cell maturation, proliferation, and survival.(16-20) Increased levels of a soluble form of BCMA (sBCMA), produced through cleavage at t…”
BackgroundXu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 391 · cited 1× · see citing works
“Therapeutic approaches such as chimeric antigen receptor T-cell therapies and bispecific T-cell engagers that use T cell–mediated cytotoxicity to target BCMA on plasma cells have shown deep responses in patients with relapsed or refractory disease.(21-25) Another class of T-cell redirecting therapy in development for…”
Backgroundγ-secretase directly sheds the survival receptor BCMA from plasma cells
Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S. M., Schuh, E., Krumbholz, M., Rübsamen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8333 · Cited by 377 · see citing works
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI
Marsters, S. A., Yan, M., Pitti, R. M., Haas, P. E., Dixit, V. M., & Ashkenazi, A. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00566-2 · Cited by 374 · cited 1× · see citing works
“Upon binding to its ligands, a proliferation-inducing ligand (APRIL; CD256) and BAFF (CD257), BCMA activates p38/NF-kB and induces upregulation of antiapoptotic proteins to regulate B-cell maturation, proliferation, and survival.(16-20) Increased levels of a soluble form of BCMA (sBCMA), produced through cleavage at t…”
BackgroundKumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · see citing works
Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 341 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundEfficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S. A. B. W., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 340 · cited 2× · see citing works
“The DuoBody antibody (JNJ-64007957 or teclistamab) was generated by controlled Fab-arm exchange of a BCMA antibody and a CD3 parental antibody derived from SP34 clone26 following the method developed by Genmab.27 Null arm controls were generated by controlled Fab-arm exchange of mouse anti-human respiratory syncytial…”
MethodTreatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Mikhael, J. R., Ismaila, N., Cheung, M. C., Costello, C. L., Dhodapkar, M. V., Kumar, S. K., Lacy, M. Q., Lipe, B. C., Little, R. F., Nikonova, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02096 · Cited by 334 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundSeckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A. L., Lipp, S., Merino, J., Prósper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 313 · cited 1× · see citing works
“BCMA is selectively expressed on late-stage B cells and plasma cells, and its expression levels correlate with myeloma tumor burden.(35) Data from a BCMA CAR-T clinical study in patients with MM has shown a high overall response with manageable safety, highlighting the potential for targeting BCMA in the clinical sett…”
BackgroundSanchez, E., Li, M., Kitto, A., Li, J. S. Y., Wang, C. S., Kirk, D. T., Yellin, O., Nichols, C. M., Dreyer, M. P., Ahles, C. P., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09241.x · Cited by 280 · cited 2× · see citing works
“Upon binding to its ligands, a proliferation-inducing ligand (APRIL; CD256) and BAFF (CD257), BCMA activates p38/NF-kB and induces upregulation of antiapoptotic proteins to regulate B-cell maturation, proliferation, and survival.(16-20) Increased levels of a soluble form of BCMA (sBCMA), produced through cleavage at t…”
BackgroundResultHatzoglou, A., Roussel, J., Bourgeade, M., Rogier, E., Madry, C., Inoue, J., Devergne, O., & Tsapis, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1322 · Cited by 241 · see citing works
Hipp, S., Tai, Y., Blanset, D. L., Deegen, P., Wahl, J., Thomas, O. S., Rattel, B., Adam, P. J., Anderson, K. C., & Friedrich, M. (2016) · Leukemia · doi:10.1038/leu.2016.388 · Cited by 234 · see citing works
Pillarisetti, K., Edavettal, S., Mendonça, M., Li, Y., Tornetta, M., Babich, A., Majewski, N., Husovsky, M., Reeves, D., Walsh, E., et al. (2020) · Blood · doi:10.1182/blood.2019003342 · Cited by 174 · cited 2× · see citing works
“Cytokine measurement Production of interferon-g, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, IL-13, and tumor necrosis factor (TNF)-a was assayed by using the Meso Scale Discovery human pro-inflammatory panel 1 kit as per the instructions.(30)”
MethodSelf-citationVafa, O., Gilliland, G. L., Brezski, R. J., Strake, B., Wilkinson, T., Lacy, E. R., Scallon, B. J., Teplyakov, A., Malia, T., & Strohl, W. R. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.035 · Cited by 154 · cited 2× · see citing works
“223 10(5) cells/mL in complete medium containing 2 mg/mL of Fc block.(29) Assay was established by using 90 mL (23 10(4)) of target cells and 90 mL (13 10(5)) of freshly thawed normal donor pan-T cells along with 20 mL of 103 concentration of antibody dilutions, and they were incubated at 37°C with 5% carbon dioxide f…”
MethodMadduri, D., Usmani, S. Z., Jagannath, S., Singh, I., Zudaire, E., Yeh, T., Allred, A. J., Banerjee, A., Goldberg, J. D., Schecter, J. M., et al. (2019) · Blood · doi:10.1182/blood-2019-121731 · Cited by 108 · see citing works
Pessano, S., Oettgen, H. C., Bhan, A. K., & Terhorst, C. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03634.x · Cited by 80 · see citing works
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kroenke, J., Facon, T., Einsele, H., & Munzert, G. (2018) · Blood · doi:10.1182/blood-2018-99-109769 · Cited by 55 · see citing works
Usmani, S. Z., Mateos, M., Nahi, H., Krishnan, A. Y., van de Donk, N. W. C. J., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Adams, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.100 · Cited by 42 · cited 1× · see citing works
“gov #NCT03145181 and #NCT04108195).(38) Acknowledgments The authors thank Brendan Weiss, Blake J.”
BackgroundSelf-citationPalumbo, A. P., Dimopoulos, M. A., Miguel, J. F. S., Harousseau, J., Attal, M., Hussein, M. A., Knop, S. T., Ludwig, H., von Lilienfeld‐Toal, M., & Sonneveld, P. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.07.003 · Cited by 40 · cited 1× · see citing works
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundCanziani, G., Melero, J. A., & Lacy, E. R. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2149 · Cited by 11 · cited 1× · see citing works
“Null arm controls were generated by controlled Fab-arm exchange of mouse anti-human respiratory syncytial virus neutralizing antibody (Null) with anti-CD3 antibody (NullxCD3) or anti-BCMA antibody (BCMAxNull).(28) Flow cytometry analysis of BCMA expression Human BM mononuclear cells (BM MNCs; ProteoGenex) and MM cell…”
MethodRossi, M., Altomare, E., Botta, C., Cantafio, M. E. G., Gaspari, M., Taverna, D., Sarvide, S., Caracciolo, D., Critelli, P., Conforti, F. S., et al. (2019) · Blood · doi:10.1182/blood-2019-122429 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 461 · see citing works
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., Karlin, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01338-6 · Cited by 335 · see citing works
Self-citationFriedrich, M., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.008 · Cited by 282 · see citing works
The landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 228 · see citing works
“Teclistamab [60], REGN5458 [61], CC-93269 [62] PF-06863135 [63], and TNB-383B”
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Tapia‐Galisteo, A., Álvarez‐Vallina, L., & Sanz, L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01482-w · Cited by 141 · see citing works
“In preclinical studies, teclistamab promoted efficient cytotoxicity of MM cells in vitro, even in the presence of sBCMA, and tumor regression in vivo [55].”
BackgroundReal-world analysis of teclistamab in 123 RRMM patients from Germany
Riedhammer, C., Bassermann, F. C., Besemer, B., Bewarder, M., Brunner, F., Carpinteiro, A., Einsele, H., Faltin, J., Frenking, J. H., Gezer, D., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02154-5 · Cited by 123 · see citing works
“It is unclear whether such discrepancies also exist for teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispeci fi c antibody [7] which was approved for treatment of RRMM in several countries in 2022.”
BackgroundAntibody‐Incorporated Nanomedicines for Cancer Therapy
Wu, S., Wu, F., & Chen, X. S. (2022) · Advanced Materials · doi:10.1002/adma.202109210 · Cited by 94 · see citing works
Rodríguez-Nava, C., Ortuño‐Pineda, C., Illades‐Aguiar, B., Flores‐Alfaro, E., Leyva‐Vázquez, M. A., Parra‐Rojas, I., Moral-Hernández, Ó. D., Vences-Velázquez, A., Cortés-Sarabia, K., & Alarcón‐Romero, L. D. C. (2023) · Biomedicines · doi:10.3390/biomedicines11061610 · Cited by 83 · see citing works
“Teclistamab-cqyv BCMA [60] Humanized Ig G4-proline, alanine, alanine Multiple myeloma 2022”
BackgroundInfluentialVerkleij, C. P. M., O’Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., Oca, R. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3333 · Cited by 87 · see citing works
Lee, H., Neri, P. E., & Bahlis, N. J. (2024) · Blood · doi:10.1182/blood.2023022499 · Cited by 79 · see citing works
Hong, Y., Nam, S.-M., & Moon, A. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01433-6 · Cited by 74 · see citing works
“It is approved for the treatment of adult patients with relapsed and refractory multiple myeloma (Pillarisetti et al. 2020).”
BackgroundCortés‐Selva, D., Perova, T., Skerget, S., Vishwamitra, D., Stein, S. J., Boominathan, R., Lau, O., Calara-Nielsen, K., Davis, C., Patel, J., et al. (2024) · Blood · doi:10.1182/blood.2023022823 · Cited by 73 · see citing works
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 61 · see citing works
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Cho, S., Yeh, T., Anderson, K. C., & Tai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032775 · Cited by 63 · see citing works
“In addition, pretreatment or combination with anti-CD38 MoAb, such as daratumumab, or a g-secretase inhibitor further enhanced MM cell lysis (37).”
BackgroundA pivotal decade for bispecific antibodies?
Surowka, M., & Klein, C. (2024) · mAbs · doi:10.1080/19420862.2024.2321635 · Cited by 64 · see citing works
“…2) the CD20/CD3ε TCEs mosunetuzumab for the treatment of R/R non-Hodgkin’s lymphoma (NHL), 51 and glofitamab 53 and epcoritamab 44 for the treatment of R/R DLBCL, and 3) the BCMA/CD3ε TCEs teclistamab 43 and elranatamab, 47 and GPRC5D/CD3ε talquetamab, 45 for the treatment of R/R multiple myeloma.”
van de Donk, N. W. C. J., Chari, A., & Mateos, M. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00186-8 · Cited by 65 · see citing works
Bispecific T‐cell engagers for treatment of multiple myeloma
Ravi, G., & Costa, L. J. (2022) · American Journal of Hematology · doi:10.1002/ajh.26628 · Cited by 59 · see citing works
Chen, H., Yu, T., Lin, L., Xing, L., Cho, S., Wen, K., Aardalen, K., Oka, A., Lam, J. W., Daley, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00716-3 · Cited by 57 · see citing works
“The first BCMA-specific Ab drug conjugate (ADC) belantamab mafodotin was approved by FDA to treat heavily pretreated RRMM in 2020 [7], quickly followed by the approval of the anti-BCMA chimeric antigen receptor (CAR)-T therapies idecabtagene vicleucel (ide-cel) [8, 9] and ciltacabtagene autoleucel [10], as well as the…”
BackgroundGirgis, S., Lin, S. X. W., Pillarisetti, K., Verona, R. I., Vieyra, D. S., Casneuf, T., Fink, D., Miao, X., Chen, Y., Stephenson, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007625 · Cited by 55 · see citing works
“Preclinical studies have also indicated that incubation with sBCMA (up to 166 nM) had minimal effect on the cytotoxicity potential of teclistamab.(13)”
BackgroundSelf-citationMarkouli, M., Ullah, F., Ünlü, S., Omar, N., Lopetegui‐Lia, N., Duco, M., Anwer, F., Raza, S., & Dima, D. (2023) · Current Oncology · doi:10.3390/curroncol30070467 · Cited by 56 · see citing works
“TEC is the only approved bsAb for clinical use in RRMM [41].”
BackgroundEpidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 56 · see citing works
Zhou, X., Rasche, L., Kortüm, K. M., Mersi, J., & Einsele, H. (2022) · Haematologica · doi:10.3324/haematol.2020.266841 · Cited by 53 · see citing works
“LY-411575 and nirogacestat, is currently under clinical investigation in phase 1 trials (80, 81).”
BackgroundCD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Firestone, R., McAvoy, D. P., Shekarkhand, T., Serrano, E., Hamadeh, I. S., Wang, A., Zhu, M., Qin, W. G., Patel, D., Tan, C. R. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011225 · Cited by 53 · see citing works
Carretero-Iglesia, L., Hall, O. J., Berret, J., Pais, D., Estoppey, C., Chimen, M., Monney, T., Loyau, J., Dreyfus, C., Macoin, J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00821-1 · Cited by 56 · see citing works
“APRIL, sBCMA and sCD38 are found at higher levels in the serum of patients with MM compared to healthy donors (HDs) (up to 50-, 10-and fourfold, respectively) 2,22,23 .”
Ramasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 54 · see citing works
Miao, X., Wu, L. S., Lin, S. X. W., Xu, Y. C., Chen, Y., Iwaki, Y., Kobos, R., Stephenson, T., Kemmerer, K., Uhlar, C., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00989-z · Cited by 47 · see citing works
“…therapies for heavily pretreated patients with RRMM. Teclistamab is the first BCMA × CD3 bispecific antibody approved for the treatment of triple-class–exposed RRMM. Teclistamab redirects CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing multiple myeloma cells [14].”
BackgroundConnolly, K., Brungs, D., Szeto, E. R., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42 · see citing works
Díez-Alonso, L., Falgàs, A., Arroyo‐Ródenas, J., Romencín, P. A., Martínez-Moreno, A., Gómez-Rosel, M., Blanco, B., Jiménez-Reinoso, A., Mayado, A., Pérez‐Pons, A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7962 · Cited by 36 · see citing works
“BCMA shedding is an obstacle to BCMA-targeted therapies both by reducing cell surface BCMA density and by acting as a decoy that neutralizes the activity of redirected T cells, as reported for BCMA-specific CAR-T cells ( 20 ); however, the impact on TCE-based therapies is considerably lower ( 21 ).”
BackgroundT-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies
Cech, P., Skórka, K., Dziki, L., & Giannopoulos, K. (2024) · Cancers · doi:10.3390/cancers16081580 · Cited by 35 · see citing works
“Teclistamab (JNJ-7957) is a humanized BsAb developed by Janssen on the Duobody platform, targeting BCMA and CD3 [96].”
BackgroundFacts and Hopes in Multiple Myeloma Immunotherapy
Sperling, A. S., & Anderson, K. C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3600 · Cited by 33 · see citing works
“Multiple other T-cell engagers targeting BCMA are now in clinical trials (70, 71).”
BackgroundTeclistamab: Mechanism of action, clinical, and translational science
Guo, Y., Cardé, N. A. Q., Kang, L., Verona, R. I., Banerjee, A., Kobos, R., Chastain, K. M., Uhlar, C., Pillarisetti, K., Doyle, M., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13717 · Cited by 33 · see citing works
“Nonetheless, patients who responded to teclistamab had higher induction of interferon-γ (IFN-γ ), interleukin-6 (IL-6), IL-10, and IL-2 receptor α , as well as surface levels of CD38 or TIM-3 on CD8 + T cells after teclistamab administration.”
BackgroundSelf-citationNovellis, D. D., Fontana, R., Giudice, V., Serio, B., & Selleri, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010645 · Cited by 32 · see citing works
Shin, H. G., Yang, H. R., Yoon, A., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105686 · Cited by 31 · see citing works
“Teclistamab (JNJ-64007957) is a CD3- and BCMA-specific bsAb-based T-cell engager based on the DuoBody platform [282].”
BackgroundAnti-BCMA novel therapies for multiple myeloma
Sammartano, V., Franceschini, M., Fredducci, S., Caroni, F., Ciofini, S., Pacelli, P., Bocchia, M., & Gozzetti, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.138 · Cited by 31 · see citing works
Moreau, P., van de Donk, N. W. C. J., Delforge, M., Einsele, H., Stefano, V. D., Perrot, A., Besemer, B., Pawlyn, C., Karlin, L., Manier, S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02480-7 · Cited by 30 · see citing works
“Teclistamab is an off-the-shelf, T-cell-redirecting, B-cell maturation antigen (BCMA) 9 CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells [13, 14].”
BackgroundBCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
Paul, B. A., Rodriguez, C., & Usmani, S. Z. (2022) · Drugs · doi:10.1007/s40265-022-01697-0 · Cited by 28 · see citing works
“Teclistamab is an IgG4 engineered antibody targeting CD3 and BCMA that showed cytotoxic activity in vitro by T cell activation and cytokine release [97].”
BackgroundMeetze, K., Mehta, N. K., Li, B.-C., Findlay, H. M., London, T. B., Patakas, A., Michaelson, J., & Baeuerle, P. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007398 · Cited by 19 · see citing works
T cell engagers emerge as a compelling therapeutic modality
Baeuerle, P. A., Sauer, K., Grieshaber‐Bouyer, R., & Michaelson, J. S. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20251652 · Cited by 25 · see citing works
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Raimondo, F. D., & Giuliani, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684561 · Cited by 24 · see citing works
“The antibody drug conjugate Belantamab mafodotin exerts anti-MM effect via several mechanisms: i. inducing ADCP via binding of the defucosylated Fc fragment of macrophages the arrest of MM cells in G2/M phase resulting in apoptosis; ii. inducing a powerful ADCC via binding of the defucosylated Fc fragment of NK and PB…”
BackgroundInfluentialBoje, A. S., Pekar, L., Koep, K., Lipinski, B., Rabinovich, B. A., Evers, A., Gehlert, C. L., Krohn, S., Xiao, Y., Krah, S., et al. (2024) · mAbs · doi:10.1080/19420862.2024.2315640 · Cited by 24 · see citing works
Allosteric antibodies: a novel paradigm in drug discovery
Fournier, L., Guarnera, E., Kolmar, H., & Becker, S. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.10.007 · Cited by 23 · see citing works
Hosny, M., Verkleij, C. P. M., van der Schans, J., Frerichs, K. A., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194593 · Cited by 24 · see citing works
Carrasco‐Padilla, C., Hernaiz-Esteban, A., Álvarez‐Vallina, L., Aguilar-Sopeña, Ó., & Roda‐Navarro, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010132 · Cited by 22 · see citing works
“Teclistamab Duobody BCMA (TNFRSF17; cancer cell) Recruitment and activation of T cells [30] Multiple myeloma Approved by EMA”
BackgroundHow multispecific molecules are transforming pharmacotherapy
Deshaies, R. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01262-w · Cited by 23 · see citing works
Pillarisetti, K., Yang, D., Luistro, L. L., Yao, J., Smith, M. L., Vulfson, P., Testa, J. S., Ponticiello, R. P., Brodeur, S. R., Heidrich, B. J., et al. (2025) · Blood · doi:10.1182/blood.2025030027 · Cited by 24 · see citing works
Self-citationBispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
Puglianini, O. A. C., & Chávez, J. C. (2021) · Drugs in Context · doi:10.7573/dic.2021-2-4 · Cited by 21 · see citing works
“5–30 mg DLBCL: 18 FL: 24 RT: 5 MCL: 5 DLBCL: 61 (54) FL: 67 (54) 64 (3.”
Park, D. H., Liaw, K., Bhojnagarwala, P. S., Zhu, X., Choi, J., Ali, A., Bordoloi, D., Gary, E. N., O’Connell, R. P., Kulkarni, A. J., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.004 · Cited by 21 · see citing works
Pouleau, B., Estoppey, C., Suere, P., Nallet, E., Laurendon, A., Monney, T., Ferreira, D. P., Drake, A. C. B., Carretero-Iglesia, L., Macoin, J., et al. (2023) · Blood · doi:10.1182/blood.2022019451 · Cited by 21 · see citing works
Girgis, S., Lin, S. X. W., Pillarisetti, K., Banerjee, A., Stephenson, T., Ma, X., Shetty, S., Yang, T., Hilder, B. W., Jiao, Q., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00893-y · Cited by 20 · see citing works
“0003 mg/kg administered intravenously once every two weeks [8], was determined from the mean 20% of maximum effect (EC20) from an in vitro cytotoxicity assay using isolated T cells [4].”
BackgroundMethodResultInfluentialSelf-citationMonoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
Luca, F. D., Allegra, A., Chio, C. D., Previti, S., Zappalà, M., & Ettari, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043136 · Cited by 20 · see citing works
“This effect occurs regardless of the specificity of the T-cell receptor or class I major histocompatibility complex molecules on the surface of myeloma cells [81].”
BackgroundTeclistamab‐cqyv in multiple myeloma
Martino, E. A., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14121 · Cited by 20 · see citing works
“24 The antibody, in particular, was found to be capable of inducing cytotoxicity of MM cell lines expressing BCMA, as well as concomitant T-cell activation and consequent cytokines release.”
BackgroundImmunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 19 · see citing works
Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
Du, Y., & Xu, J. (2021) · Advanced Materials · doi:10.1002/adma.202103114 · Cited by 19 · see citing works
Designing Multivalent and Multispecific Biologics
Kang, J. J., Ohoka, A., & Sarkar, C. A. (2023) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100722-112440 · Cited by 19 · see citing works
The making of multispecific immunoglobulins – a clinical perspective
Brinkmann, U., & Kontermann, R. E. (2026) · mAbs · doi:10.1080/19420862.2026.2613548 · Cited by 19 · see citing works
Martin, T. G., Moreau, P., Usmani, S. Z., Garfall, A. L., Mateos, M., Miguel, J. F. S., Oriol, A., Nooka, A. K., Rosiñol, L., Chari, A., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.11.001 · Cited by 17 · see citing works
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain, M., Yellapragada, S. V., & Hadidi, S. A. (2023) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s272703 · Cited by 17 · see citing works
Structure and function of therapeutic antibodies approved by the US FDA in 2024
Strohl, W. R. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf014 · Cited by 15 · see citing works
Advances in the clinical application of bispecific antibodies in cancer therapy
Zhou, S., Feng, L., Niu, M., Wu, K., Li, T., & Yi, M. (2025) · iScience · doi:10.1016/j.isci.2025.114203 · Cited by 15 · see citing works
Murtadha, M., Park, M., Zhu, Y., Caserta, E., Napolitano, O., Tandoh, T., Moloudizargari, M., Pozhitkov, A. E., Singer, M., Donà, A., et al. (2024) · Blood · doi:10.1182/blood.2023021570 · Cited by 15 · see citing works
Liao, X., Qi, T., Zhou, J., Liu, C., & Cao, Y. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3302 · Cited by 15 · see citing works
Lang, Y., Lyu, Y., Tan, Y., & Hu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195194 · Cited by 14 · see citing works
Greenberg, R. S., Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Garonzik‐Wang, J., Segev, D. L., & Imus, P. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-09097-5 · Cited by 14 · see citing works
“Teclistamab induces T cell-mediated destruction of B-cell maturation antigen (BCMA) positive B-cells [16].”
BackgroundPan, D., & Richter, J. R. (2023) · Cancer Management and Research · doi:10.2147/cmar.s372237 · Cited by 13 · see citing works
“Activated T cells also release cytokines such as IL-2, IL-6, IL-10, and IFNγ which contribute to their efficacy.(1,11) Preclinical studies have found no association between degree of BCMA expression on myeloma samples and teclistamab efficacy.”
BackgroundTargeting BCMA in Multiple Myeloma
Tan, C. R. C., & Shah, U. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00639-z · Cited by 12 · see citing works
Targeting CD276 for T cell-based immunotherapy of breast cancer
Hagelstein, I., Wessling, L., Rochwarger, A., Zekri, L., Klimovich, B., Tegeler, C. M., Jung, G., Schürch, C. M., Salih, H. R., & Lutz, M. S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05689-4 · Cited by 12 · see citing works
“…of impressive clinical results with bsAbs include the CD20 and CD3 targeting bsAbs mosunetuzumab as well as glofitamab for the treatment of relapsed or refractory lymphoma [23–25] and the BCMA-directed constructs teclistamab as well as elranatamab for treatment of multiple myeloma [26, 27].”
BackgroundVolta, L. G., Myburgh, R., Hofstetter, M., Koch, C., Kiefer, J. D., Gobbi, C., Manfredi, F., Zimmermann, K., Kaufmann, P. A., Fazio, S., et al. (2024) · HemaSphere · doi:10.1002/hem3.70055 · Cited by 12 · see citing works
Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review
Sangwan, K., Sharma, V., & Goyal, P. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230622151034 · Cited by 12 · see citing works
When and How to Treat Relapsed Multiple Myeloma
Nathwani, N., Bertamini, L., Banerjee, R. K., Gay, F., Shah, N. D., & Krishnan, A. Y. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320129 · Cited by 12 · see citing works
Multi-targeted immunotherapeutics to treat B cell malignancies
Gambles, M. T., Yang, J., & Kopec̆ek, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.048 · Cited by 11 · see citing works
Why Immunotherapy Fails in Multiple Myeloma
Rodríguez‐Lobato, L. G., Oliver‐Caldés, A., Moreno, D. F., de Larrea, C. F., & Bladé, J. (2020) · Hemato · doi:10.3390/hemato2010001 · Cited by 11 · see citing works
“In preclinical studies, the drug proved capable of recruiting and activating T cells to direct their cytotoxicity against BCMA+ MM cells from an MM cell line (H929) and in BM samples obtained from patients with MM as well [113].”
BackgroundBarilà, G., Rizzi, R., Zambello, R., & Musto, P. (2021) · Pharmaceuticals · doi:10.3390/ph14010040 · Cited by 11 · see citing works
“Teclistamab (formerly JNJ-64007957) is a humanized IgG-4 bases BCMA × CD3 bispecific antibody that induces T cell-mediated cytotoxicity against BCMA-expressing MM cells [63].”
BackgroundTaking a BiTE out of the CAR T space race
Patel, A., Oluwole, O. O., Savani, B. N., & Dholaria, B. (2021) · British Journal of Haematology · doi:10.1111/bjh.17622 · Cited by 10 · see citing works
Straßl, I., Schreder, M., Steiner, N., Rudzki, J. D., Agis, H., Kunz, T., Müser, N., Willenbacher, W., Petzer, A. L., Neumeister, P., et al. (2021) · Cancers · doi:10.3390/cancers13184701 · Cited by 10 · see citing works
Applications of pharmacometrics in drug development
Xiong, Y., Samtani, M. N., & Ouellet, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115503 · Cited by 9 · see citing works
Guo, Y., Niu, J., Cardé, N. A. Q., Wu, L. S., Miao, X., Hanson, S., Su, Y., Pérez‐Ruixo, C., Vishwamitra, D., Chastain, K. M., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01149-1 · Cited by 9 · see citing works
“The pharmacokinetics (PK) and pharmacodynamics (PD) of teclistamab have previously been characterized in detail, supporting the selection of the recommended phase II dose (RP2D) of subcutaneous (SC) teclistamab 1.5 mg/ kg QW following step-up dosing [17–20].”
InfluentialGrahnert, A., Seiffert, S., Wenk, K., Schmiedel, D., Boldt, A., Vučinić, V., Merz, M., Platzbecker, U., Klemann, C., Koehl, U., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081641 · Cited by 8 · see citing works
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
Jamroziak, K., Zielonka, K., Khwaja, J., & Wechalekar, A. D. (2025) · British Journal of Haematology · doi:10.1111/bjh.19960 · Cited by 10 · see citing works
Charkviani, M., Vargas-Brochero, M. J., Mohan, A., Vaughan, L. E., Sandahl, T. B., Corraes, A. D. M. S., Lin, Y., Leung, N., & Herrmann, S. M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf004 · Cited by 8 · see citing works
Li, W., Zhao, D., Yu, J., Dong, W., Wang, Z., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565407 · Cited by 8 · see citing works
Teclistamab impairs detection of BCMA CAR-T cells
Glatte, B., Wenk, K., Grahnert, A., Friedrich, M., Merz, M., Vučinić, V., Fischer, L., Reiche, K., Alb, M., Hudecek, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009714 · Cited by 8 · see citing works
Wijnands, C., Karel, P. G. A., Gloerich, J., Armony, G., Tzasta, A., Angelino, C. M. D. K., Stéfano, L. D., Bonifay, V., Luider, T. M., VanDuijn, M. M., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010135 · Cited by 7 · see citing works
“…advancements in the field of MM therapeutics have led to the development of new agents including T-cell-redirecting bispecific antibodies (bsAbs) which bind simultaneously to CD3 on the T-cell and to an epitope present on MM cells (e.g., BCMA for teclistamab or GPRC5D for talquetamab) [7,8].”
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Fine, J., Meksiriporn, B., Tan, J., & Spangler, J. B. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-102155 · Cited by 7 · see citing works
Haustrate, A., Cordier, C., Shapovalov, G., Mihalache, A., Desruelles, E., Soret, B., Essonghé, N. C., Spriet, C., Yassine, M., Barras, A., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06809-0 · Cited by 7 · see citing works
Xie, Z., & Protzer, U. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105972 · Cited by 7 · see citing works
Melflufen for the treatment of multiple myeloma
Ocio, E. M., Nadeem, O., Schjesvold, F. H., Gay, F., Touzeau, C., Dimopoulos, M. A., Richardson, P. G. G., & Mateos, M. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2075847 · Cited by 7 · see citing works
“CC93269, teclistamab) [13,14], antibody-drug conjugates (e.”
Lapietra, G., Fazio, F., & Petrucci, M. T. (2022) · Biomolecules · doi:10.3390/biom12081146 · Cited by 7 · see citing works
“In vitro assays showed that this drug induces cytotoxicity of BCMA+ cells through multiple mechanisms, including dose-dependent lysis, T-cell activation, and cytokine release, especially if in the presence of a γ-secretase inhibitor [71].”
BackgroundWang, M., Wang, C., Deng, J., Wang, H., Sun, C., Luo, S., & Hu, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906216 · Cited by 9 · see citing works
“Teclistamab is a humanized IgG bsAb that targets BCMA and CD3 [40].”
BackgroundBispecific Antibodies for the Treatment of Multiple Myeloma
Goldsmith, S. R., Streeter, S., & Covut, F. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00675-3 · Cited by 6 · see citing works
Update on bi-specific monoclonal antibodies for blood cancers
Shouse, G. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000966 · Cited by 6 · see citing works
Large scale controlled Fab exchange GMP process to prepare bispecific antibodies
Yao, X., Xie, M., Ben, Y., Zhu, Y., Yang, G., Kwong, S. C. W., Zhang, Z., & Chiu, M. L. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1298890 · Cited by 6 · see citing works
Willemin, M., Lin, S. X. W., Zwart, L. D., Wu, L. S., Miao, X., Verona, R. I., Banerjee, A., Liu, B., Kobos, R., Qi, M., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13144 · Cited by 6 · see citing works
“17,18 The accelerated approval of te-clistamab was based on the pivotal portion of the phase I/ II MajesTEC-1 trial (NCT03145181/NCT04557098), which assessed the efficacy and safety of teclistamab at the recommended phase II dose (RP2D; once weekly 1.5 mg/kg subcutaneous) in patients with TCE RRMM.…”
MethodInfluentialBispecific Antibodies in the Treatment of Multiple Myeloma
Zhou, X., Xiao, X., Kortuem, K. M., & Einsele, H. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.003 · Cited by 5 · see citing works
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4 · see citing works
“In co-culture experiments, low concentrations of sBCMA, APRIL or BAFF did not interfere with the cytotoxic effect [33].”
Kim, H., & Kim, Y. K. (2025) · Han-guk hyeonmigyeong hakoeji/Applied microscopy · doi:10.1186/s42649-024-00106-y · Cited by 4 · see citing works
“For example, researchers can utilize CLEM to observe how a BsAb engages with tumor cells and the resultant formation of immune synapses in real-time (Chan et al. 2018; Pillarisetti et al. 2020).”
Wang, Z., Song, Y., Guo, H., Yan, Y., Ma, L., & Liu, B. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01290-z · Cited by 3 · see citing works
“Teclistamab, a bispecific antibody targeting BCMA and CD3 from the surface of T cells, mediates T cell activation and lysis of BCMA-expressing myeloma cells [33].”
BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis
Lewis, E., & Jimenez-Zepeda, V. H. (2025) · Current Oncology · doi:10.3390/curroncol32080418 · Cited by 3 · see citing works
Menon, V. C. A., Matsuura, T., Holkova, B., Gudi, G. S., Drake, A. C. B., Pihlgren, M., van der Graaf, P. H., Gn, S., Garton, A., Perro, M., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70319 · Cited by 3 · see citing works
Kikuchi, J., Osada, N., Matsuoka, S., Yasui, H., Furukawa, Y., & Nakasone, H. (2025) · Leukemia · doi:10.1038/s41375-025-02792-3 · Cited by 3 · see citing works
- Authors
- Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., Chin, D., Packman, K., Elsayed, Y., Attar, R., & Gaudet, F.
- Affiliations
- Oncology and
- Janssen Research & Development (United States) (US)
- IBM (United States) (US)
- Legend Biotech (United States) (US)
- Century Therapeutics (United States) (US)
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-09-21
- Volume
- 4
- Issue
- 18
- Pages
- 4538-4549
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7509877
- OpenAlex
- W3087111554
- Cited by
- 144
- References
- 40
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 31 · 2023: 27 · 2022: 19 · 2021: 20 · 2020: 1 · 2013: 1
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- teclistamab, BCMA, multiple myeloma, bispecific antibodies, T cell redirection, T cell activation, gamma-secretase inhibitors, tumor cell lysis, xenograft models, relapsed/refractory multiple myeloma
- MeSH terms
- Animals, Humans, Lymphocyte Activation, Multiple Myeloma, T-Lymphocytes, Antibodies, Bispecific, Mice, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
